Recruiting studies: Spinal And Bulbar Muscular Atrophy

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

A Study of Tinengotinib (TT-00420) in Combination With Standard Treatments in People With Prostate Cancer
Phase 1/Phase 2 · 12 location(s) · Memorial Sloan Kettering Cancer Center · NCT06457919 ARCTIC: Liquid Biomarkers in the Prospective Androgen Receptor Signaling Inhibitors (ARSI) Resistance Clinical Trials
Phase N/A · 3 location(s) · Duke University · NCT06141993 TherApeutics in Early ProState Cancer (TAPS02)
Phase 2 · 6 location(s) · Cambridge University Hospitals NHS Foundation Trust · NCT05191680 A Phase III Study Comparing HRS-4357 With Novel Androgen Receptor Pathway Inhibitors in Patients With Progressive, PSMA-
Phase 3 · 1 location(s) · Jiangsu HengRui Medicine Co., Ltd. · NCT07311694 A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants Wit
Phase 3 · 281 location(s) · Celgene · NCT06764485 A Study to Investigate the Safety and Tolerability of Oral INR731 Single Agent or in Combination With Androgen Receptor
Phase 1 · 3 location(s) · Novartis Pharmaceuticals · NCT07570979 Hyperandrogenemia and Altered Day-night LH Pulse Patterns
EARLY_Phase 1 · 1 location(s) · University of Virginia · NCT03068910 Apa/Enza-short Study: Shorter Treatment With Androgen Receptor Pathway Inhibitor in Patients With Low-volume Metastatic
Phase 3 · 26 location(s) · Nick Beije · NCT07260435 Metastasis-directed Therapy for Oligorecurrent Prostate Cancer
Phase 3 · 1 location(s) · Universitaire Ziekenhuizen KU Leuven · NCT05352178 Androgen Receptor, Implications for Health and Wellbeing: Natural History Study of Individuals With Androgen Insensitivi
Phase N/A · 1 location(s) · Eunice Kennedy Shriver National Institute of Child Health an · NCT04708431 Stereotactic Body Radiation Therapy Plus Immediate or Delayed Androgen Receptor Pathway Inhibitor and Androgen Deprivati
Phase 2 · 3 location(s) · Mayo Clinic · NCT06378866 Supraphysiologic Testosterone Priming Induces Darolutamide Extended Response
Phase 2 · 1 location(s) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · NCT07142551 An Observational Study to Learn More About How Medicines That Block Male Hormones Are Used in People With Prostate Cance
Phase N/A · 1 location(s) · Bayer · NCT07223372 Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC
Phase 3 · 88 location(s) · Novartis Pharmaceuticals · NCT06855277 Abemaciclib in Combination With Bicalutamide for Androgen Receptor-positive, HER2-negative Metastatic Breast Cancer
Phase 1/Phase 2 · 3 location(s) · Icahn School of Medicine at Mount Sinai · NCT05095207 UK SMA Patient Registry
Phase N/A · 1 location(s) · Newcastle University · NCT04292574 Clinical Trial of Mexiletine Hydrochloride for Spinal and Bulbar Muscular Atrophy
Phase 2/Phase 3 · 5 location(s) · Masahisa Katsuno · NCT06862596 A Phase Ib/II Open-label Study of AMO959 With Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI i
Phase 1/Phase 2 · 21 location(s) · Novartis Pharmaceuticals · NCT07226986 Study Evaluating the Safety, Tolerability, and Efficacy of Xaluritamig in Combination With Androgen Receptor Pathway Inh
Phase 1 · 16 location(s) · Amgen · NCT07140900 Prostate Cryoablation Combined With Metronomic Cyclophosphamide for Metastatic Prostate Cancer
Phase 2 · 1 location(s) · Sun Yat-sen University · NCT06854250 Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and S
Phase 3 · 395 location(s) · Canadian Cancer Trials Group · NCT06592924 Evaluation of PSMA in HER2- AR+ Metastatic Breast Cancer
Phase 2 · 1 location(s) · University of Wisconsin, Madison · NCT04573231 Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
Phase N/A · 2 location(s) · Sanford Health · NCT01793168 START-MET HS Prostate Cancer. : SbrT & Androgen Receptor Therapy METastatic HSPC
NA · 2 location(s) · Instituto de Investigación en Oncología Radioterápica - Fund · NCT05209243 Phase I/II Trial of Pembrolizumab and Androgen-receptor Inhibitor With or Without 225Ac-J591 for Progressive Metastatic
Phase 1/Phase 2 · 4 location(s) · Weill Medical College of Cornell University · NCT04946370 Novel ACK1 Inhibitor (R)-9b in Patients With Prostate Cancer
Phase 1 · 1 location(s) · TechnoGenesys, Inc. · NCT06705686 Evaluation of Clinical Outcomes of Chemotherapy or Androgen-receptor Targeting Agent (Alone or Combined) or Radiotherapy
Phase N/A · 3 location(s) · Santa Chiara Hospital · NCT06473259 ADT +/- Darolutamide in de Novo Metastatic Prostate Cancer Patients With Vulnerable Functional Ability (PEACE6-Vulnerabl
Phase 3 · 95 location(s) · UNICANCER · NCT04916613 Clinical, Molecular and Imaging Biomarkers in Spinal and Bulbar Muscular Atrophy (SBMA)
Phase N/A · 1 location(s) · National Institute of Neurological Disorders and Stroke (NIN · NCT04944940 Everolimus With Investigator's Choice of Chemotherapy in Advanced Triple-Negative Breast Cancer (TNBC) With Luminal Andr
Phase 3 · 1 location(s) · Fudan University · NCT05954442

Look up another condition

Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.